Historical brief · 2026-11-15

FDA rejects Summit Therapeutics' ivonescimab for lung cancer

The FDA has denied approval for Summit Therapeutics' ivonescimab to treat a specific type of lung cancer. The agency stated that the drug failed to demonstrate a statistically significant overall survival benefit, blocking its entry into the U.S. market despite its prior availability in China.

Source image · BioSpace Drug Development

Rejection Details

Summit Therapeutics faced a setback as the FDA issued a complete response letter denying approval for its PD-1xVEGF bispecific antibody, ivonescimab, targeting EGFR-mutated non-small cell lung cancer after TKI inhibitor treatment. The regulatory agency argued that although the drug improved progression-free survival in the Phase 3 HARMONi trial, the absence of a statistically significant overall survival benefit means the therapy lacks a positive benefit-risk profile in its current form.

Industry Context

Ivonescimab, originally developed and partnered through China's Akeso where it became available in 2024, has drawn massive attention from major pharmaceutical companies and analysts who viewed it as a potential blockbuster backbone in oncology. Despite presenting updated global data showing slight overall survival benefits earlier, Summit must now re-evaluate its path forward for this indication while continuing trials in other cancer types.

View selection rationale
Media reportStage not established

Importance 79/100

Signal85Structure80Consequence72Confidence85Momentum85
About this brief
Content type
News summary
Source type
Publisher report
Source published
Process
AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
Verification
The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
Published by
Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
Conflict disclosure
No financial or commercial conflict declared.

Editorial standards → · Corrections →

POLYEMERGENCE / EXPLORE

Keep exploring

Follow the topic, not just the headline.

Explore the Biotech & Programmable Life archive →